Monte Rosa Therapeutics, Inc. (GLUE)
USD 3.63
(-8.1%)
USD 3.63
(-8.1%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -43.8 Million | -92.46 Million | -59.36 Million | -23.05 Million | -6.17 Million |
| Net Income | -135.35 Million | -108.5 Million | -73.95 Million | -35.87 Million | -7.74 Million |
| Depreciation & Amortization | 6.22 Million | 3.74 Million | 2.13 Million | 537 Thousand | 72 Thousand |
| Deferred income taxes | -5.75 Million | - | 17 Thousand | - | - |
| Stock-based compensation | 16.66 Million | 11.66 Million | 5.2 Million | 354 Thousand | - |
| Change in working capital | 72.46 Million | -2.13 Million | 6.28 Million | 4.25 Million | 1.77 Million |
| Other non-cash items | 1.95 Million | 2.76 Million | 960 Thousand | 7.68 Million | -276 Thousand |
| Investing Cash Flow | 88.8 Million | -219.21 Million | -9.65 Million | -3.38 Million | -1.38 Million |
| Investments in PPE | -19.04 Million | -12.91 Million | -9.73 Million | -3.38 Million | -1.38 Million |
| Acquisitions | 62 Thousand | 109 Thousand | 79 Thousand | - | - |
| Investment purchases | -103.15 Million | -384.41 Million | - | - | - |
| Sales/Maturities of investments | 210.93 Million | 178 Million | - | - | - |
| Other Investing Activities | 107.84 Thousand | -206.3 Thousand | 79.00 | - | - |
| Financing Cash Flow | 27.49 Million | 20.46 Million | 377.56 Million | 60.06 Million | 15 Million |
| Debt repayment | - | - | - | - | -750 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | -440 Thousand | - |
| Common Stock Issuance | 27.49 Million | 20.46 Million | 377.56 Million | 60.06 Million | 14.25 Million |
| Other Financing Activities | -116 Thousand | 20.46 Million | 377.56 Million | 440 Thousand | 750 Thousand |
| Accounts receivables | 1897.00 | -187.00 | - | - | - |
| Accounts payables | 5.75 Million | -744 Thousand | -706 Thousand | 3.43 Million | 2.86 Million |
| Inventory | -1897.00 | 187.00 | - | - | - |
| Other working capital | 66.7 Million | -1.39 Million | 6.99 Million | 820 Thousand | -1.08 Million |
| Cash at beginning of period | 55.87 Million | 351.4 Million | 42.86 Million | 9.24 Million | 1.8 Million |
| Cash at end of period | 128.1 Million | 60.19 Million | 351.4 Million | 42.86 Million | 9.24 Million |
| Capital Expenditure | -19.04 Million | -12.91 Million | -9.73 Million | -3.38 Million | -1.38 Million |
| Effect of forex changes on cash | -262 Thousand | - | - | - | - |
| Net cash flow / Change in cash | 72.22 Million | -291.21 Million | 308.54 Million | 33.61 Million | 7.44 Million |
| Free Cash Flow | -62.84 Million | -105.37 Million | -69.09 Million | -26.44 Million | -7.55 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -30.31 Million | -31.96 Million | -33.25 Million | -135.35 Million | -34.88 Million | -35.17 Million |
| Depreciation & Amortization | 2.06 Million | 1.89 Million | 1.84 Million | 6.22 Million | 1.83 Million | 1.39 Million |
| Deferred income taxes | - | - | -1.99 Million | -5.75 Million | - | - |
| Stock-based compensation | 4.5 Million | 4.87 Million | 4.07 Million | 16.66 Million | 4.46 Million | 4.15 Million |
| Change in working capital | -2.92 Million | -12.89 Million | 57.7 Million | 72.46 Million | 4.37 Million | 5.74 Million |
| Other non-cash items | 16.46 Million | 13.67 Million | 1.26 Million | 1.95 Million | -497 Thousand | -1.43 Million |
| Investing Cash Flow | -61.15 Million | 9.85 Million | 14.29 Million | 88.8 Million | 35.62 Million | 18.55 Million |
| Investments in PPE | -2.02 Million | -1.38 Million | -1.68 Million | -19.04 Million | -1.65 Million | -6.51 Million |
| Acquisitions | - | - | -15.98 Thousand | 62 Thousand | -37.28 Thousand | 62 Thousand |
| Investment purchases | -73.95 Million | -56.06 Million | -27.51 Million | -103.15 Million | -7.81 Million | -62 Thousand |
| Sales/Maturities of investments | 14.82 Million | 67.3 Million | 43.5 Million | 210.93 Million | 45.1 Million | 25 Million |
| Other Investing Activities | -59.13 Million | 11.23 Million | 15.98 Thousand | 107.84 Thousand | 37.28 Thousand | 62 Thousand |
| Financing Cash Flow | 98.02 Million | 246 Thousand | 25.17 Million | 27.49 Million | 1.1 Million | 1.2 Million |
| Debt repayment | - | - | - | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | 98.02 Million | 246 Thousand | 25.17 Million | 27.49 Million | 1.1 Million | 1.2 Million |
| Other Financing Activities | 98.02 Million | 246 Thousand | 25.17 Thousand | -116 Thousand | 1101.00 | 1200.00 |
| Accounts receivables | -9.32 Million | -10 Thousand | -336.00 | 1897.00 | 375 Thousand | -195 Thousand |
| Accounts payables | 394 Thousand | -5.07 Million | 5.76 Million | 5.75 Million | 686 Thousand | -1 Million |
| Inventory | - | - | 336.00 | -1897.00 | -375 Thousand | 195 Thousand |
| Other working capital | 6 Million | -7.81 Million | 51.93 Million | 66.7 Million | 3.68 Million | 6.75 Million |
| Cash at beginning of period | 99.75 Million | 128.1 Million | 59.05 Million | 55.87 Million | 51.55 Million | 57.12 Million |
| Cash at end of period | 108.84 Million | 99.75 Million | 128.1 Million | 128.1 Million | 63.57 Million | 51.55 Million |
| Capital Expenditure | -2.02 Million | -1.38 Million | -1.68 Million | -19.04 Million | -1.65 Million | -6.51 Million |
| Effect of forex changes on cash | - | - | -58 Thousand | -262 Thousand | - | - |
| Net cash flow / Change in cash | 9.09 Million | -28.34 Million | 69.04 Million | 72.22 Million | 12.02 Million | -5.57 Million |
| Free Cash Flow | -29.78 Million | -39.54 Million | 27.94 Million | -62.84 Million | -26.36 Million | -31.83 Million |
CPHN
0IUX
NOTE-WT
KARIN
IDN
3167